AU2003223340A1 - Certain pharmaceutically useful substituted aminoalkyl heterocycles - Google Patents

Certain pharmaceutically useful substituted aminoalkyl heterocycles

Info

Publication number
AU2003223340A1
AU2003223340A1 AU2003223340A AU2003223340A AU2003223340A1 AU 2003223340 A1 AU2003223340 A1 AU 2003223340A1 AU 2003223340 A AU2003223340 A AU 2003223340A AU 2003223340 A AU2003223340 A AU 2003223340A AU 2003223340 A1 AU2003223340 A1 AU 2003223340A1
Authority
AU
Australia
Prior art keywords
pharmaceutically useful
substituted aminoalkyl
certain pharmaceutically
useful substituted
heterocycles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003223340A
Other languages
English (en)
Other versions
AU2003223340A8 (en
Inventor
Ajita Bhat
James S. Frazee
Lara S. Kallander
Chum Ma
Joseph P. Marino
Michael J. Neeb
Scott K. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2003223340A1 publication Critical patent/AU2003223340A1/en
Publication of AU2003223340A8 publication Critical patent/AU2003223340A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
AU2003223340A 2002-03-27 2003-03-26 Certain pharmaceutically useful substituted aminoalkyl heterocycles Abandoned AU2003223340A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36841502P 2002-03-27 2002-03-27
US60/368,415 2002-03-27
PCT/US2003/009039 WO2003082192A2 (en) 2002-03-27 2003-03-26 Certain pharmaceutically useful substituted aminoalkyl heterocycles

Publications (2)

Publication Number Publication Date
AU2003223340A1 true AU2003223340A1 (en) 2003-10-13
AU2003223340A8 AU2003223340A8 (en) 2003-10-13

Family

ID=28675483

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003223340A Abandoned AU2003223340A1 (en) 2002-03-27 2003-03-26 Certain pharmaceutically useful substituted aminoalkyl heterocycles

Country Status (8)

Country Link
US (1) US7323494B2 (https=)
EP (1) EP1490047B1 (https=)
JP (1) JP2005521705A (https=)
AT (1) ATE453389T1 (https=)
AU (1) AU2003223340A1 (https=)
DE (1) DE60330758D1 (https=)
ES (1) ES2337037T3 (https=)
WO (1) WO2003082192A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509161A (ja) * 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
EP1487776A4 (en) 2002-03-27 2005-05-25 Smithkline Beecham Corp ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
US20050171084A1 (en) * 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
US7247748B2 (en) 2002-03-27 2007-07-24 Smithkline Corporation Amide compounds and methods of using the same
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
IL166149A0 (en) * 2005-01-05 2006-01-15 Hadasit Med Res Service Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity
ES2380499T3 (es) 2006-11-30 2012-05-14 Kowa Company. Ltd. Compuesto de Carbinol sustituido
US7919509B2 (en) 2008-02-29 2011-04-05 Kowa Company, Ltd. 2-oxochromene derivatives
US7951822B2 (en) 2008-03-31 2011-05-31 Kowa Company, Ltd. 1,3-dihydroisobenzofuran derivatives
WO2009133692A1 (ja) 2008-04-30 2009-11-05 興和株式会社 キノリン化合物
JP5541803B2 (ja) 2008-05-29 2014-07-09 興和株式会社 環状リンカーを有する置換カルビノール化合物
CN102438991B (zh) 2009-04-29 2015-08-26 兴和株式会社 具有杂环连接基的甲醇化合物
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
CN110494415A (zh) 2017-03-03 2019-11-22 睿治尼斯公司 具有改善的稳定性的制剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3889545T2 (de) 1987-10-20 1994-10-13 Otsuka Pharma Co Ltd Phenylcarbonsäure-abkömmlinge.
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
AU2000235960A1 (en) 2000-02-14 2001-08-27 Tularik, Inc. Lxr modulators
JP2004509161A (ja) 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体
US20030229062A1 (en) 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
JP2005511713A (ja) 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20050171084A1 (en) 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
US7247748B2 (en) 2002-03-27 2007-07-24 Smithkline Corporation Amide compounds and methods of using the same
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
EP1487776A4 (en) 2002-03-27 2005-05-25 Smithkline Beecham Corp ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
WO2004058175A2 (en) 2002-12-23 2004-07-15 Irm Llc Novel use of liver x receptor agonists
GB0230177D0 (en) 2002-12-24 2003-02-05 Karobio Ab LXR beta crystal
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
US20060189693A1 (en) 2003-07-22 2006-08-24 Barone Frank C Methods of treatment with lxr agonists
EP1653938A2 (en) 2003-07-28 2006-05-10 Glaxo Group Limited Methods of treatment of inflammatory bowel disease with lxr agonists
WO2005055998A1 (en) 2003-12-04 2005-06-23 Smithkline Beecham Corporation Methods of treatment with lxr agonists
RU2006124843A (ru) 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
EP1758651A2 (en) 2004-06-24 2007-03-07 Galapagos N.V. Lxr agonists to promote bone homeostasis
US20080255111A1 (en) 2004-07-02 2008-10-16 Sankyo Company Limited Tissue Factor Production Inhibitor

Also Published As

Publication number Publication date
JP2005521705A (ja) 2005-07-21
US7323494B2 (en) 2008-01-29
DE60330758D1 (de) 2010-02-11
WO2003082192A2 (en) 2003-10-09
WO2003082192A3 (en) 2003-12-18
AU2003223340A8 (en) 2003-10-13
ES2337037T3 (es) 2010-04-20
EP1490047A2 (en) 2004-12-29
EP1490047A4 (en) 2006-01-04
EP1490047B1 (en) 2009-12-30
US20050165045A1 (en) 2005-07-28
ATE453389T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
WO2003082205A3 (en) Compounds and methods
AU2002211216A1 (en) Substituted aminopropoxyaryl derivatives useful as agonists for lxr
DE69831868D1 (en) Antithrombosemittel
AU2003223340A1 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
AU2002950217A0 (en) 8- Hydroxy Quinoline Derivatives
ATE297203T1 (de) Antithrombotische mitteln
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
AU2001280438A1 (en) Substituted heterocyclic amides
IL143545A0 (en) Thrombin inhibitors
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
GB0111523D0 (en) Chemical compounds
GB9914486D0 (en) Medicaments
AU7558900A (en) Tetrahydroquinoline derivatives
GB0214149D0 (en) Chemical compounds
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
WO2003049690A3 (en) Hiv integrase inhibitors
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
PL359415A1 (en) Oxadiazole derivatives having anticancer effects
DE60114640D1 (en) Antithrombosemittel
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
WO2003093247A3 (en) Antibacterial agents
WO2004089943A8 (en) Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues
AU2002248531A1 (en) Pyrazolopyriadine derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase